Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial

AIDS Behav. 2024 Sep;28(9):2990-3000. doi: 10.1007/s10461-024-04382-3. Epub 2024 Jun 9.

Abstract

We evaluated correlates of adherence to PrEP, including daily oral tenofovir disoproxil fumarate in combination emtricitabine (oral FTC/TDF) and the monthly dapivirine ring (ring)among adolescent girls and young women (AGYW) in the MTN-034/REACH study. We enrolled 247 AGYW aged 16-21 years in South Africa, Uganda and Zimbabwe (ClinicalTrials.gov: NCT03074786). Participants were randomized to the order of oral FTC/TDF or ring use for 6 months each in a crossover period, followed by a 6-month choice period. We assessed potential adherence correlates-individual, interpersonal, community, study, and product-related factors-quarterly via self-report. We measured biomarkers of adherence monthly; high adherence was defined as > 4 mg dapivirine released from returned rings or intracellular tenofovir diphosphate levels ≥ 700 fmol/punch from dried blood spots (DBS). We tested associations between correlates and objective measures of high adherence using generalized estimating equations. High adherence to oral FTC/TDF was significantly associated with having an older primary partner (p = 0.04), not having exchanged sex in the past 3 months (p = 0.02), and rating oral FTC/TDF as highly acceptable (p = 0.003). High ring adherence was significantly associated with unstable housing (p = 0.01), disclosing ring use to a male family member (p = 0.01), and noting a social benefit from study participation (p = 0.03). All associations were moderate, corresponding to about 6%-10% difference in the proportion with high adherence. In our multinational study, correlates of adherence among African AGYW differed for oral FTC/TDF and the ring, highlighting the benefit of offering multiple PrEP options.

Keywords: Adherence; Africa; Heterosexual women; Pre-exposure prophylaxis (PrEP).

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Intravaginal
  • Administration, Oral
  • Adolescent
  • Anti-HIV Agents* / administration & dosage
  • Contraceptive Devices, Female / statistics & numerical data
  • Cross-Over Studies*
  • Emtricitabine / administration & dosage
  • Female
  • HIV Infections* / prevention & control
  • Humans
  • Medication Adherence* / statistics & numerical data
  • Pre-Exposure Prophylaxis* / methods
  • Pyrimidines / administration & dosage
  • South Africa
  • Tenofovir / administration & dosage
  • Tenofovir / therapeutic use
  • Uganda
  • Young Adult
  • Zimbabwe

Substances

  • Anti-HIV Agents
  • Dapivirine
  • Tenofovir
  • Pyrimidines
  • Emtricitabine

Associated data

  • ClinicalTrials.gov/NCT03074786